Fig. 2: Duration of study participation and efficacy assessment for the per-protocol population of 67 cases. | British Journal of Cancer

Fig. 2: Duration of study participation and efficacy assessment for the per-protocol population of 67 cases.

From: First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial

Fig. 2

Objective response: Patient achieved partial or complete response according to the Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) and the consensus guidelines for assessment of response to immune-modulating therapies (iRECIST).

Back to article page